Last reviewed · How we verify
Metronidazole Topical Gel 2%
Metronidazole disrupts bacterial and protozoal DNA, causing cell death and reducing inflammation in topical infections.
Metronidazole disrupts bacterial and protozoal DNA, causing cell death and reducing inflammation in topical infections. Used for Rosacea (topical), Bacterial vaginosis (topical), Inflammatory acne.
At a glance
| Generic name | Metronidazole Topical Gel 2% |
|---|---|
| Sponsor | Jinnah Postgraduate Medical Centre |
| Drug class | Nitroimidazole antimicrobial |
| Target | Bacterial/protozoal DNA |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
Metronidazole is a nitroimidazole that penetrates microbial cells and is reduced to reactive intermediates that damage DNA and inhibit nucleic acid synthesis. When applied topically as a gel, it reduces pathogenic bacteria and protozoa while also possessing anti-inflammatory properties that help resolve rosacea and other inflammatory skin conditions.
Approved indications
- Rosacea (topical)
- Bacterial vaginosis (topical)
- Inflammatory acne
- Perioral dermatitis
Common side effects
- Local irritation or burning
- Dryness or peeling
- Metallic taste (if absorbed systemically)
- Contact dermatitis
Key clinical trials
- Pharmacokinetics of Transdermal Metronidazole (PHASE4)
- Metronidazole 2% Gel Versus Clindamycin 1% Gel for Moderate Acne Vulgaris (PHASE4)
- Evaluation of Relapse, Efficacy and Safety of Long-term Treatment With Oracea® vs Placebo (PHASE4)
- An Evaluation of the Cosmetic Appearance of Metronidazole Gel (MetroGel®) 1%
- A Therapeutic Equivalence Study of Two Metronidazole Gel 1% Topical Treatments of Rosacea (PHASE3)
- Locally Delivered Antibiotics for the Treatment of Periodontitis (NA)
- Study to Evaluate the Efficacy and Safety of PAC-14028 Cream in Rosacea Patients (PHASE2)
- A Therapeutic Equivalence Study of Two Metronidazole 1%Topical Gel Treatments for Patients With Rosacea (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Metronidazole Topical Gel 2% CI brief — competitive landscape report
- Metronidazole Topical Gel 2% updates RSS · CI watch RSS
- Jinnah Postgraduate Medical Centre portfolio CI